---
title: "1910: AI Drug Discovery Branding Brief | FIFTYSEVEN"
url: "https://www.fiftyseven.co/work/1910"
description: "1910 Genetics, now 1910, AI-driven drug discovery: the 2026 repositioning as an AI-native platform for pharma, with a new identity, the website, the founder video and the full explainer of the ITO™ platform by FIFTYSEVEN, in five months. The company debuted with $26M in 2021, per GlobeNewswire, and has raised $40M to date across seed, Series A and Series A-2, per its investor page."
---

1910 Genetics, now 1910, AI-driven drug discovery: the 2026 repositioning as an AI-native platform for pharma, with a new identity, the website, the founder video and the full explainer of the ITO™ platform by FIFTYSEVEN, in five months. The company debuted with $26M in 2021, per GlobeNewswire, and has raised $40M to date across seed, Series A and Series A-2, per its investor page.

Industry:

- All
- AI
- Architecture
- Automotive
- Biotechnology
- Chartering
- Climate Tech
- Digital Platform
- E-Commerce
- Fintech
- Healthcare
- Holding / VC
- SaaS
- Tech
- Telecommunication
- Wearable

Scroll

# 1910

## Visual (13) eloquence.

[N° #Holding / VC #Tech #AI On-Edge U.S.A. Case Brief](https://www.fiftyseven.co/work/on-edge)

[N° #Biotechnology #Healthcare #Tech #AI 1910 AI U.S.A. Case Brief](https://www.fiftyseven.co/work/1910)

[N° #Healthcare #Wearable #Tech #AI Happy Ring U.S.A. Case Brief](https://www.fiftyseven.co/work/happy-ring)

[N° #Climate Tech #Tech DePoly SA Switzerland Case Study](https://www.fiftyseven.co/case/depoly)

[N° #Biotechnology #Healthcare #Tech Roswell Biotech U.S.A. Case Study](https://www.fiftyseven.co/case/roswell-biotech)

[N° #Biotechnology #Healthcare #Tech #AI 1910 Genetics U.S.A. Case Study](https://www.fiftyseven.co/case/1910-genetics)

[N° #Digital Platform #Healthcare Enzian Health Switzerland Case Study](https://www.fiftyseven.co/case/enzian-health)

[N° #Digital Platform #SaaS Kollabo AG Switzerland Case Study](https://www.fiftyseven.co/case/kollabo-ag)

[N° #Climate Tech #Fintech #SaaS Yova AG Switzerland Case Brief](https://www.fiftyseven.co/work/yova)

[N° #Tech #Sensor Technology Tacterion Germany Case Brief](https://www.fiftyseven.co/work/tacterion)

[N° #Biotechnology #Healthcare #Tech Koniku U.S.A. Case Brief](https://www.fiftyseven.co/work/koniku)

[N° #SaaS #AI Risqly IO Canada View Website](https://www.risqly.io/)

[N° #E-Commerce Sensilia/Pernixol France View Website](https://www.sensilia.com/)

## NEXT FRAME( 6 )

More work, still

taking shape.

Open

1910

- Industry: AI Drug Discovery, Biotech
- Country: U.S.A.
- Timeline: 5 months
- Service(s): 17
  - Competitive Analysis
  - Creative Direction
  - Art Direction
  - Brand Identity
  - Brand Application
  - Design System
  - Photography Art Direction
  - Videography Art Direction
  - Pitch Deck Design
  - Graphic Design
  - Illustration
  - 3D Visualization
  - Video & Motion
  - Web UX Design
  - Web UI Design
  - Webflow Development
  - Content Management System
- Sector: [Biotech & Life Sciences](https://www.fiftyseven.co/industries/biotech)

Overview Objectives Approach Results

Founded in 2018 in Boston, 1910 Genetics began with two AI platforms, ELVIS for small molecule drugs and ROSALYND for protein therapeutics, and one aim: "to make undruggable targets a thing of the past".

In 2026 it relaunched as 1910 and put the platform to work across pharma, as "an infrastructure for AI-enabled drug discovery". The stated ambition goes further: to make every pharma company an AI company.

- Reposition a company that had proven its platform as one that now deploys it, for pharma partners.
- Bring technical credibility into the first meeting: an entry point built for enterprise sales and big pharma.
- Explain a platform in three parts through visual storytelling, without drifting into the science, for a business development reader with ten minutes and a mandate.

The second engagement started where the first ended, with a different company: a new offering, a new positioning and everything rebuilt from the start, colour, symbol and system, while the core message and the founding vision stayed. The technology would no longer be explained in an image and a short clip; it would be walked through, component by component, each backed by the scientific logic and the proof behind it. The look and feel: an enterprise-grade company, confident in the rooms it now enters.

A new identity, the website, the founder video and the full explainer of the ITO™ platform in its three parts, AI-driven Precision Target ID, AI-driven Molecular Design & Optimization and Federated Learning, launched in February 2026, five years after [the studio's first brand and website for the company](https://www.fiftyseven.co/case/1910-genetics).

That earlier engagement launched in late 2020; the following March the company debuted publicly with $26M, per GlobeNewswire. From there the company went on to $40M in all, across seed, Series A and Series A-2, per its investor page, and came to 2026 with a platform proven and a position to take.

[Visit Website](https://www.1910.ai/)

01:32

Play